Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 7/20 | 0.34 |
| ▸ | EBP | Q15125 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25745792 | 0.84 | CRHR1 (0.39) | CRHR1SLC2A1SLC2A2SLC2A3SLC16A3 | |
| SCHEMBL24815457 | 0.82 | CNR2 (0.39) | SLC2A1SLC2A2SLC2A3SLC16A3SLC16A1 | |
| SCHEMBL24007868 | 0.82 | PDE8B (0.37) | SLC2A1SLC2A2SLC2A3SLC16A3SLC16A1 | |
| SCHEMBL26013186 | 0.80 | CNR2 (0.39) | SLC16A3SLC16A1CNR2CNR1KCNH2 | |
| SCHEMBL25746032 | 0.76 | SLC2A1 (0.32) | SLC2A1SLC2A2SLC2A3CNR2EBP | |
| SCHEMBL24007602 | 0.76 | GRM2 (0.32) | SLC2A1SLC2A2SLC2A3CNR2EBP | |
| SCHEMBL24007879 | 0.70 | SLC2A1 (0.43) | CRHR1SLC2A1SLC2A2SLC2A3CNR2 | |
| SCHEMBL24006951 | 0.69 | PDE4D (0.36) | CNR2CNR1KCNH2SLC5A1 | |
| SCHEMBL25745791 | 0.69 | CRHR1 (0.42) | CRHR1CNR2CNR1GRM2 | |
| SCHEMBL24816297 | 0.69 | TLR7 (0.41) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CRHR1 3851/4885CRHR2 3485/4885SLC2A1 4352/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | CRHR1 3851/4885CRHR2 3485/4885SLC2A1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.